A client who is newly diagnosed with diabetes insipidus is receiving a synthetic vasopressin intravenously. Which side effect of vasopressin reported by the client should the nurse report to the healthcare provider?

A) Request a prescription to change the route of administration and use the available heparin:
Changing the route of administration without a prescription is not within the nurse's scope of practice and could lead to medication errors or adverse effects. It's essential to follow the prescribed route of administration to ensure patient safety.

B) Calculate and administer the equivalent dose of the available low molecular weight heparin:
Low molecular weight heparin (LMWH) has different dosing and potency compared to unfractionated heparin. Calculating an equivalent dose without a specific conversion ratio could result in under- or overdosing, leading to ineffective anticoagulation or increased risk of bleeding.

C) Advise the pharmacy of the need to deliver a vial of heparin to the nursing unit immediately:
This is the correct action. Since the prescription specifies unfractionated heparin administered intravenously, the nurse should notify the pharmacy to provide the correct medication promptly. Using a different form of heparin could lead to dosing errors or ineffective treatment.

D) Dilute the available heparin in 250 mL of normal saline solution prior to IV administration:
This action is not appropriate because it assumes that the available heparin is suitable for intravenous administration, which may not be the case. Dilution may also alter the concentration and potency of the medication, leading to inaccurate dosing and potential adverse effects.

A) Undergo annual eye examinations:
While methotrexate and adalimumab can both have potential ocular side effects, such as blurred vision or eye pain, the need for annual eye examinations is more commonly associated with methotrexate therapy. Methotrexate can cause ocular toxicity, including retinopathy and optic neuropathy, which necessitates regular monitoring by an ophthalmologist. However, adalimumab is not typically associated with annual eye examinations, so this instruction is not directly relevant to the addition of adalimumab to the client’s regimen.

B) Have a chest x-ray prior to your first dose:
A chest x-ray is not routinely required before initiating adalimumab therapy. While screening for tuberculosis (TB) may be necessary in clients starting adalimumab due to its immunosuppressive effects, a chest x-ray is not always indicated for this purpose. Instead, TB screening usually involves a thorough history, physical examination, and possibly tuberculin skin testing or interferon-gamma release assays. Therefore, this instruction is not specifically related to the addition of adalimumab to the client’s treatment regimen.

C) Avoid crowds and people who are sick:
Adalimumab is a biologic disease-modifying antirheumatic drug (DMARD) that suppresses the immune system’s inflammatory response by targeting tumor necrosis factor-alpha (TNF-alpha). As a result, clients taking adalimumab are at increased risk of infections, including bacterial, viral, and fungal infections. Therefore, instructing the client to avoid crowds and individuals who are sick helps reduce the risk of exposure to infectious pathogens and minimize the likelihood of developing infections while on adalimumab therapy.

D) Obtain routine vaccinations as scheduled:
While maintaining up-to-date vaccinations is important for overall health and immunity, clients receiving biologic DMARDs like adalimumab may have a reduced response to vaccines due to immunosuppression. Therefore, it is generally recommended to administer necessary vaccinations before starting adalimumab therapy whenever possible. However, the decision to administer vaccines should be individualized, and certain live vaccines may be contraindicated while receiving adalimumab. Nonetheless, this instruction is not directly related to the addition of adalimumab to the client’s medication regimen.